Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue During Hematopoetic Stem Cell Transplantation for Multiple Myeloma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 73
- 试验地点
- 1
- 主要终点
- FACIT-Fatigue Scale
研究概览
简要总结
A sample of 60 patients scheduled for HSCT in the treatment of MM will be recruited in the weeks to months prior to their hospitalization. Light therapy incorporating ambient Programmed Environmental Illumination (PEI) will be used in patient hospital rooms (during scheduled transplant) to control cancer-related fatigue (CRF). The FDA has certified that light therapy, like that used in this study, is a low-risk intervention. When admitted to the hospital for a stem cell transplant, there will be a light fixture in the hospital room which the researchers will be testing to see how it may affect cancer related fatigue, sleep quality, and other negative side effects often seen with the transplant and subsequent treatment. The light fixture will turn on and off by itself in the morning. There are two treatment arms used in the study, each of the arms uses different light intensities. The study treatment received, i.e. which of the two lights, will be chosen by chance, like flipping a coin. There is an equal chance of being given each study treatment. Participants will not be told which study treatment they are getting until after the study is completed. Each light will be turned on from 7 AM to 10AM every day during transplantation. While in the hospital, assessment of fatigue, sleep activity, depression, circadian rhythms, and quality of life will continue through the course of hospitalization (14-21 days of treatment, to determine immediate impact of sPI), then repeat at one month and three months post-discharge follow-ups (to determine lasting effects). Outcomes will be assessed through standardized scales (e.g., FACIT-Fatigue Scale) and objective measures (e.g., actigraphy, daysimeter for light monitoring, melatonin from urine collection, blood inflammatory markers, all explained below). This trial will: 1) be the first randomized clinical trial (RCT) to investigate the effects of sPI to prevent CRF and other biopsychosocial side effects of transplant; 2) focus on a distinct, relatively homogenous patient population (MM-HSCT patients) with high prevalence of CRF; and 3) explore possible circadian rhythm mediation via melatonin analysis and blood analysis. This investigation will have major public health relevance as it will determine if an inexpensive and low patient burden intervention (sPI) is able to control fatigue associated with medical illnesses and related problems.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Double (Participant, Care Provider)
盲法说明
Neither the study participant nor the research coordinator know that study condition of the patient.
入排标准
- 年龄范围
- 21 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Who will undergo their first autologous HSCT procedure as treatment for multiple myeloma
- •Who are currently 21 years of age or older
- •English language proficient
- •Able to provide informed consent
排除标准
- •Under age 21
- •Previous HSCT procedure (autologous or allogeneic)Pregnancy
- •Eye Diseases which limit the ability of light to be processed (e.g., untreated cataracts, severe glaucoma, macular degeneration, blindness, pupil dilation problems or retina damage)
- •Secondary cancer diagnosis within the last 5 years
- •Severe sleep disorders (e.g., Narcolepsy)
- •History of bipolar disorder or manic episodes (which is a contra-indication for light treatment)
- •Severe psychological impairment (e.g., hospitalization for depressive episode in the past 12 months)
- •Previous use of light therapy to alleviate fatigue or depressive symptoms
结局指标
主要结局
FACIT-Fatigue Scale
时间窗: Baseline, Day 2, 7, 14, 28 and 90
The FACIT-Fatigue scale is a13 item scale, full scale 0-52, with higher score indicating better functioning or less fatigue.
次要结局
- CES-D (Center for Epidemiologic Studies Depression Scale)(Baseline, Day 2, 7, 14, 28, and 90)
- Multidimensional Fatigue(up to 3 months)
- The Pittsburgh Sleep Quality Index(Baseline, Day 30 and Day 90)
- SF-36 Scale(Baseline and 30 days post hospital discharge)
- Number of Participants With Score 16 or Greater on CES-D (Center for Epidemiologic Studies Depression Scale)(Baseline, Day 2, Day 7, and Day 14 post transplant)
- The Positive and Negative Affect Schedule (PANAS)(Baseline, Day 30, Day 90)
- Change in Brief Symptoms Inventory-18 (BSI-18)(Baseline and Day 90)
- Fatigue Line Scale(baseline, day 2, 7, and 14)
- Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF)(Baseline, Day 30 after Discharge, Day 90 after Discharge)
- Sleep Latency(Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge)
- Sleep Efficiency(Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge)
- Wake Time(Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge)
- Wake Percent(Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge)
- Sleep Time(Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge)
- Sleep Percent(Baseline, Day 2, Day 7, 3rd day post Engraftment, Discharge)
- Melatonin(Baseline and Discharge)
研究者
William H. Redd
Associated Professor
Icahn School of Medicine at Mount Sinai
